Src tyrosine kinase (Src) is implicated in the development of bone metastasis and castration resistance of prostate cancer. Src inhibitors are currently being tested in clinical trials for such diseases. Understanding the molecular and cellular actions of Src inhibitors holds the key to future improvement of this line of therapy. Here we describe the microRNA expression profiles modulated by two Src inhibitors and demonstrate that the miR-30 family members are the most prominently induced species. Consistent with its tumor suppressor role, miR-30 is downmodulated by oncogenic signals such as epidermal growth factor (EGF) and hepatocyte growth factor, and is generally underexpressed in prostate cancer specimens. A number of epithelial-tomesenchymal transition (EMT)-associated genes are predicted targets of miR-30. Among these genes the Ets-related gene (ERG) is the most frequently overexpressed oncogene in prostate cancer activated by genomic fusion events between promoter upstream sequences of the TMPRSS2 and coding sequences of ERG. We showed by ERG 3 0 untranslated region reporter and mutagenesis assays that ERG is a direct target of miR-30. Overexpression of miR-30 in prostate cancer cells suppresses EMT phenotypes and inhibits cell migration and invasion. It also inhibits the in vitro and in vivo growth of VCaP cells, which depends on TMPRSS2-ERG for proliferation. TMPRSS2-ERG is generally regulated by androgen at the transcriptional level. Our finding reveals a new post-transcriptional mechanism of TMPRSS2-ERG regulation by Src and growth signals via miR-30 providing a rationale for targeting ERG-positive castration-resistant tumors with Src inhibitors.
INTRODUCTION
Src tyrosine kinase (Src) is widely expressed and implicated in the development of human malignancies including castration-resistance prostate cancer. 1, 2 In mouse models, Src was found to synergize with the androgen receptor (AR) in the transformation of prostate epithelial cells to invasive adenocarcinoma. 3 We showed previously that in prostate cancer cells, Src is complexed with focal adhesion kinase and Etk tyrosine kinases, which transphosphorylate one another to induce migration and invasion. 4 Src also regulates osteoclastic activity and promotes bone metastasis of prostate cancer cells. 5, 6 Regarding its role in castration-resistant prostate cancer, Src is shown to activate AR in androgen-depleted conditions and facilitates the translocation of AR into nucleus upon activation by growth factors, cytokines and chemokines. 4, [7] [8] [9] In addition, Src directly phosphorylates, stabilizes and translocates AR to chromatin target sites. [9] [10] [11] Although Src is able to activate AR and serves as its coactivator, Src is reciprocally activated by AR and acts as a downstream effector for AR signaling both in a genomic and non-genomic manner. 3, 12 Thus, there is considerable evidence connecting Src signals to prostate carcinogenesis, raising the possibility of targeting Src kinase as a potential therapy. Previous studies demonstrated that Src selective inhibitors such as saracatinib and dasatinib were effective in inhibiting growth, adhesion, migration and invasion of prostate cancer cells in vitro. 13, 14 In preclinical models, the primary effects of Src inhibitors appear to be the blockade of metastasis- 14 We showed that Src inhibitors arrested cell cycle progression but did not induce significant apoptosis, owing largely to the concurrent induction of autophagy, which confers a survival advantage. 15 The addition of an autophagy inhibitor effectively overcomes the apoptosis resistance of Src inhibitor-treated prostate cancer cells. Presently, several commercial-specific oral Src kinase inhibitors are being tested in phase I and II clinical trials for the treatment of patients with prostate cancer. 16, 17 To improve the efficacy of Src inhibitors and its potential use as an adjunctive therapy, it is imperative to understand the Src kinase signals affected by the treatments. Src kinases channel signals through the conventional Ras/Raf/ERK and PI3K/Akt/mTOR pathways, 18 but also selectively activate Stat3, 19 c-myc 19 and b-catenin. 20 These Src-induced signals were attenuated in saracatinib-treated PC3 cells.
14 In addition to phsophorylation signals, Src activation also leads to the up-and down-modulation of a variety of microRNAs (miRNAs) involved in transformation and oncogenesis. 21 Few of these miRNA studies were conducted in prostate cancer cells and the effects of Src inhibitor on the expression of these oncomirs remain unknown.
Ets-related gene (ERG) is the most frequently overexpressed and translocated oncogene in prostate cancer cells 22, 23 and over 50% of prostate cancer specimens carry a translocation involving the 5 0 promoter upstream sequences of the TMPRSS2, an androgenregulated gene, and 3 0 coding exons of ERG, resulting in a TMPRSS2-ERG fusion transcripts. 24 Most of the ERG-coding sequences are retained in the fusion transcript, which in the context of gene fusion is under the transcriptional control of androgens. TMPRSS2-ERG appears to be a specific biomarker for prostate cancer cells, as normal prostate epithelial cells and benign prostatic hyperplasia do not harbor such a translocation. Engineered mice with prostate-specific overexpression of ERG develop cellular morphology that resembles precursor-like lesions of human prostate cancer. [25] [26] [27] When complemented with lesions in the PI3K pathway, progressive prostatic adenocarcinomas were induced in these mouse models. 28 Knockdown of ERG diminishes the proliferative, invasive and migratory ability of prostate cancer cells both in vitro and in vivo. 26, 29, 30 In addition, ERG downstream  targets (EZH2,  31 FZD4,  32 ZEB1 33 and C-MYC 30 ) also mediate ERG-induced epithelial-to-mesenchymal transition (EMT) and block epithelial differentiation. In experimental models TMPRSS2 to ERG translocation can be induced by radiation when combined with activation of AR. 31, 34, 35 Under androgen-deprived conditions, in a subset of relapsed tumors, abundant ERG expression, however, could be identified and in castration-resistant VCaP xenograft model harboring TMPRSS2-ERG translocation, ERG expression is maintained under castration conditions. 36 The persistent expression of ERG in a subset of castration-resistant prostate cancer cases prompted us to investigate other modes of ERG activation that are not solely dependent upon external androgen. In the present study, we report the identification of an alternative pathway, whereby ERG expression can be upregulated by epidermal growth factor (EGF) and Src via miRNA modulation. Our study has revealed a new crosstalk between the EGF/Src and androgen/AR signaling axes.
RESULTS

Src inhibitors upregulate miR-30 in VCaP cells
To investigate miRNAs regulated by c-Src kinase during the progression of advanced prostate cancer, vertebral metastatic lesion-derived VCaP cells were treated for 24 h with saracatinib (AstraZenca) or PP2 (Pfizer), selective inhibitors of Src-family tyrosine kinases, and the associated changes in miRNA abundance were analyzed by microarrays (containing 132 miRNAs, Signosis). The testing of two different Src inhibitors was intended to minimize the off-target effects of these inhibitors. In the analysis, only miRNAs commonly regulated by both inhibitors were scored. Compared with the control untreated cells, 10 miRNAs were upregulated and 13 miRNAs were downregulated more than 1.5-fold by both inhibitors. Among these miRNAs, the miR-30 family (including miR-30a-5p and miR-30b) was most increased (Figure 1a Figure 1) . These studies confirmed the microarray data of miR-30 upregulation by Src inhibitors, and showed that such upregulations are not restricted to VCaP cells.
If Src inhibitors upregulate miR-30, Src agonist should suppress miR-30 expression. Signaling by EGF or its receptor (EGFR) is known to activate Src in prostate cancer cells. 9 When VCaP cells were treated with EGF, the expression level of miR-30a (Figure 1c , left panel) and miR-30b (Figure 1c , right panel) were significantly suppressed by EGF treatment, as expected. By contrast, treatment with gefitinib, an inhibitor of EGFR, upregulated both miR-30a and miR-30b. In addition, the EGF-induced miR-30 downregulation could be completely offset by blocking Src activity with PP2, indicating Src is a major mediator of EGFs modulation of miR-30. We also tested interleukin-6 and hepatocyte growth factor, two ligands known to activate Src via their respective receptors; 4 both suppressed the expression of miR-30, although their potencies are not as high as EGF (Figure 1c [37] [38] [39] they support the notion that the miR-30 family may be associated with tumor suppressor functions in prostate cancer. We analyzed the expression pattern of miR-30a and miR-30b in prostate cancer cell lines by qRT-PCR. All prostate cancer cell lines tested expressed a modest but significant level of miR-30, which is lower than the immortalized normal epithelial-derived cell line RWPE-1 (Figure 2a) . We then analyzed miR-30 expression in a series of clinical specimens. The mean expression level of miR-30a-5p (Figure 2b , left panel) and miR-30b (Figure 2b , right panel) in tumor samples are significantly lower than that of the benign tissues, consistent with an early report that demonstrated the downmodulation of miR-30 in hormone-refractory prostate cancer, 38 as well as prostate CD44 þ cancer stem cell population. 40 Ectopic expression of miR-30 inhibits EMT To test whether miR-30 functionally behaves as a tumor suppressor, we stably overexpressed miR-30b in VCaP and PC3 using lentiviral vector carrying mature miR-30b sequence. As a major effect of Src-inhibitor is the suppression of tumor invasion and metastasis, we were particularly interested in the effect of miR-30 on genes related to metastasis/EMT. qRT-PCR was used to measure these genes in pooled populations of VCaP overexpressing miR-30b. Strikingly, the majority of the EMT-associated genes tested were downmodulated by miR-30b overexpression. They include ZEB1, TWIST, ZEB2, SPARC, MMP3 and LIN28, with BMP7, N-cadherin (CDH2), ERG, Notch1 and SNAI1 being the most severely (480%) affected (Figure 3a ). These data suggest that miR-30b inhibits EMT. Further evaluation of the role of miR-30b in EMT modulation was carried out by immunostaining of N-cadherin and E-cadherin ( Figure 3b ). In this study, we also included cells infected with lentivirus carrying anti-miR30b (antagomir against miR-30b). We found that miR-30b overexpression leads to an increase of E-cadherin and a decrease of N-cadherin expression, and the reverse is true for anti-miR30b. Next, we examined the effect of miR-30 on cell migration and invasion using Transwell assay. The cell invasion ability was significantly restrained (Po0.05, Figure 3c ) in miR-30b-overexpressing VCaP cells. We next overexpressed miR-30b in PC3 cells and showed with wound scratch assay that PC3 cells overexpressing miR-30b migrate much more slowly than the control cells ( Figure 3d ). Furthermore, to examine whether miR-30 is involved in the suppression of Srcregulated EMT, anti-miR30a/b was overexpressed in VCaP cells followed by treatment with saracatinib in the Transwell migration assay. Overexpression of anti-miR30a/b reversed the inhibition of VCaP migration by saracatinib (Supplementary Figure 2) . Taken together, these results suggest that miR-30 functions to maintain the epithelial phenotype and inhibits migration, invasion and EMT of prostate cancer cells.
miR-30 directly targets the ERG 3
0 untranslated region (3 0 UTR)
In the EMT genes tested in Figure 3a , ERG was among the most severely suppressed by miR-30. In addition, the expression level of ERG was significantly higher in the human prostate cancer specimens compared with the benign prostatic hyperplasia specimens (Supplementary Figure 3) , whereas the miR-30 expression level was lower in prostate cancer and higher in benign prostatic hyperplasia tissue ( Figure 2b ). Computational prediction Figure 4a ). 293T cells were transfected with the UTR reporter plus the negative control miRNA (miR-NC), miR-30a or miR-30b. Only transfection of miR-30a and miR-30b with the wild-type UTR reporter led to a significant decrease of luciferase activity, whereas co-expression of the antagomirs of miR-30 has no effect on the reporter activities (Figure 4d ). In addition, the suppressive effects of miR-30a and miR-30b were abolished with the mutant UTR reporter in which the seed sequences were altered (Figure 4e ). Together, these results demonstrate that miR-30 directly targets the ERG 3 0 UTR, thereby reducing TMPRSS2-ERG expression.
TMPRSS2-ERG expression is regulated by EGF signaling Our data above showed that inhibiting Src signals augments the expression of miR-30 and that miR-30 negatively regulates ERG expression. As Src is activated by EGF (via EGFR), we then asked whether inhibiting Src or EGFR would inhibit the expression of TMPRSS2-ERG. We first tested the role of EGF in TMPRSS2-EGR Figure 1 . Src inhibitors upregulate miR-30. (a) Total RNA (5 mg) from VCaP cells treated with dimethyl sulfoxide (DMSO), saracatinib (Sara, 2 mM) or PP2 (10 mM) for 24 h were subjected to Cancer miRNA array assay (Signosis). Each of 132 cancer-related miRNA was represented as duplicated spots. Arrow points to miR-30b (insert panel). Compared with the DMSO control, the relative expression level changes greater than 1.5-fold of miRNAs under both treatments are indicated. (b) miR-30a (left panel) and miR-30b (right panel) relative expression levels in response to treatment with DMSO, Sara (2 mM) or PP2 (10 mM) for 24 h were detected by qRT-PCR and normalized with U6 small nuclear RNA in VCaP and PC3 cells. (c) miR-30a (left) and miR-30b (right) expression levels (as measured by qRT-PCR) following indicated treatments for 24 h in VCaP cells; interleukin (IL)-6 (100 ng/ml), hepatocyte growth factor (50 ng/ml), EGF (10 ng/ml), gefitinib (1 mM) and pre-treatment of PP2 (10 mM) for 30 min followed by EGF treatment (E þ PP2). *Po0.05; **Po0.01; ***Po0.005. Figure 5a , showed that TMPRSS2-ERG was indeed induced dose dependently by EGF in VCaP cells. VCaP cells were then treated with increasing doses of the EGFR inhibitor AG1478 (AstraZeneca) and Src inhibitors (saracatinib and PP2), and the TMPRSS2-ERG expression was monitored with western blotting (Figure 5b ) and qRT-PCR (Figure 5c ). Inhibition of either EGFR signal or Src activity downmodulated TMPRSS2-ERG expression both at the protein and transcript level (Figures 5b and c) . These data support the hypothesis that TMPRSS2-ERG is regulated by EGF and Src signaling through miR-30 modulation. Thus, we have identified a new way to modulate TMPRSS2-ERG or ERG expression in an androgen-independent manner. To our knowledge, this is the first report that showed the modulation of ERG by growth factors and tyrosine kinases.
Ectopic expression of miR-30 and tumorigenesis TMPRSS2-ERG is known to have a critical role in the malignant transformation of prostate cancer cells. Knockdown of ERG is found to be associated with decreased proliferation, invasion and metastasis of prostate cancer cells in vitro and in vivo. 30, 33 If ERG is an important target of miR-30, we should observe a similar phenotype of miR-30b overexpressor to ERG knockdown cells. To this end, we prepared VCaP cells infected with lentiviral-short hairpin RNA targeting ERG to establish a pool of VCaP/shERG cells. There was a significant inhibition of cell growth in response to overexpression of miR-30b or knockdown ERG in VCaP cells compared with the control cells (Figure 6a ). To determine whether overexpression of miR-30b decreased cell growth in vivo, the genetically modified cell lines were subcutaneously injected into NOD/SCID mice. Serial weekly measurements showed tumor growth was suppressed in VCaP/miR-30b implants compared with vector control (Figure 6b ).
DISCUSSION
An alternative way of modulating ERG expression Increasing evidence suggests that overexpression of TMPRSS2-ERG has a significant role in the transformation, EMT and invasion of prostate cancer. In primary tumors, the major driver of the overexpression of TMPRSS2-ERG is androgen. In the present study, we have identified a new signaling pathway, which connects EGF and Src signaling to ERG activation and EMT. This connection is made through the silencing of the miR-30b locus, which targets ERG at its 3 0 UTR. This alternative mode of modulation at the RNA level should be independent of and complement to the transcriptional regulation mediated by the androgen/AR axis. We also provide data showing EGFR and Src inhibitions are able to modulate TMPRSS2-ERG expression. This is especially relevant in castration-resistant prostate cancer where the AR is aberrantly activated in the absence androgen. By targeting the RNA stability or translation, Src inhibitor offers another way of downmodulating ERG expression.
Src and miRNA modulation Src mediates oncogenesis by modulating oncogenes as well as oncomirs. 41 miR-30 was among the oncomirs downmodulated in Src-transformed cells. 21 We report here that miR-30a-5p and miR30b are the two top upregulated miRNAs by the Src selective inhibitor saracatinib. Similar findings using PP2 substantiated the specificity of the observed response. In a previous study, showed that miR-30b and miR-30c were upregulated by both EGFR and MET in lung cancer cells. 42 This discrepancy is most likely due to the cell type specificity and the complex signal network induced by EGF/EGFR. EZH2 overexpression in advanced prostate cancer leads to epigenetic silencing of developmental regulators and tumor suppressor genes. Regulation of EZH2 that catalyzes trimethylation of histone H3 on Lys27 (H3K27me3) is typically associated with gene repression. Consistent with the observation that Src inhibitor (bosutinib) downmodulates EZH2, 43 we found that Src activation increases the recruitment of EZH2 and H3K27me3 marks on miR-30b locus in VCaP cells (Supplementary Figure 5) . The exact mechanism as to how Src signal activates EZH2, which in turn, suppresses the expression of miR-30 remains to be elucidated. Other common miRNAs upregulated by both Src inhibitors include Let7i, which targets C-MYC. It has long been recognized that Src transcriptionally activates C-MYC. The detailed mechanisms are not fully understood. Let7i suppression by Src signals could be one reason how C-MYC is activated by Src, and miR-30's suppression could be another, as miR-30's target ERG is known to be a direct activator of C-MYC. 22, 27, 30 The role of miRNA-30 in prostate cancer miR-30 was described as a 'hub' for miRNA oncogenesis signal network in solid tumors. 37 Its up-or downmodulation has profound impacts on tumorigenesis. In this report, we showed that miR-30 is downmodulated in prostate cancer cells, especially at the metastatic stage. Porkka et al. 38 has identified 15 miRNAs whose expressions are reduced in castration-resistant prostate cancer and miR-30a-5p, miR-30b and miR-30c are among them. Liu et al. 40 showed that miR-30a-5p, miR-30c are commonly downmodulated in three CD44 þ cancer stem cell lines. Downmodulation of miR-30 is also found in a variety of tumors. 38, 39 This is consistent with the tumor suppressor role of miR-30, which has been shown to induce cellular senescence by negatively regulating B-MYB, 44 inhibit self-renewal and metastasis of breast tumor-initiating cells, 45 repress the stem cell and cancer phenotypes via targeting LIN28, 46 and suppress EMT and invasive potential of anaplastic thyroid carcinomas. 47 Perhaps, noncoincidentally, a significant fraction of predicted miR-30 direct targets are involved in EMT. We showed potential targets, ERG, SNAI1, SPARC, MMP3, Notch1, LIN28, and ZEB1/ZEB2, are all downmodulated in response to miR-30b overexpression. We have demonstrated that ERG is a direct target of miR-30. Downregulation of ZEB1, TWIST, ZEB2, SPARC, MMP3 and LIN28, miR-30 connects Src to EMT C-J Kao et al BMP7, CDH2, ERG, Notch1 and SNAI1 may either be direct response to miR-30 or secondary to ERG. Prior studies showed SNAIL1 and vimentin are two direct targets of miR-30, which inhibits transforming growth factor-b-induced EMT in one case 48 and confers an epithelial phenotype to human pancreatic cells in the other case. 49 Consistent with miR-30's role in suppressing EMT, we found VCaP cells overexpressing miR-30b display reduced expression of N-cadherin and lower migratory and invasive ability. Our qRT-PCR results showed that many EMT genes are downmodulated in VCaP. A similar trend is also observed for PC3 cells expressing ETV4, a close homolog of ERG 50 (data not shown). Our data as well as others taken together suggest that miR-30b is a key modulator of EMT, and miR-30's effect is further augmented in VCaP cells by its direct targeting of ERG. In addition to the reversion of EMT, targeting ERG by miR-30b also resulted in the inhibition of VCaP growth both in vitro and in vivo. Recent study has shown that miR-30b/c target caspase-3, which in turn, regulated TRAIL-induced apoptosis in glioblastoma cells. 51 However, in our previous study, neither saracatinib nor PP2 induced any caspase-3 activity or apoptosis in prostate cancer cells. 15 Accordingly, no significant apoptosis regulation by miR30a/b was seen. The results of the present study, and the consistent observation of reduced expression of miR-30 in human prostate cancer specimens, suggest that miR-30 is a bona-fide tumor suppressor in the context of prostate cancer. Restoration of miR-30 function, either by itself or in conjunction with other therapies, may improve the survival by inhibiting the growth and metastasis of castration-resistant prostate cancer.
MATERIALS AND METHODS
Cell cultures and chemicals
All cell lines were obtained from the American Type Culture Collection. PC-3, LNCaP, CWR22rv1, and Du-145 cells were cultured in RPMI 1640 (Cellgro, Manassas, VA, USA) supplemented with 10% fetal bovine serum (Cellgro), 1% penicillin and streptomycin (Invitrogen/Life Technologies, Grand Island, NY, USA). 293T and VCaP cells were cultured in Dulbecco's Modified Eagle's medium (Cellgro) with 10% fetal bovine serum, 1% penicillin and streptomycin. RWPE-1, benign human prostate epithelial cell line (American Type Culture Collection), was cultured in keratinocyte serum-free media supplemented with bovine pituitary extract and EGF 
Plasmids
The UTR reporter plasmid was constructed by introducing a 42-base pair miR-30 seed sequence-containing ERG 3 0 UTR fragment into the 3 0 end of firefly luciferase gene in the pCDNA3-Luc vector, which was constructed by cloning the firefly luciferase-coding region into the KpnI/BamHI sites of pCDNA3 (Invitrogen). The wild-type or mutant ERG 3 0 UTR complementary oligonucleotides were purchased from Integrated DNA Technology (Coralville, IW, USA) and annealed in buffer containing 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, and 2 mM magnesium acetate. To generate short hairpin RNA against ERG, we designed single-stranded primer oligos targeting sequence (5 0 -GGTGAAAGAATATGGCCTTCCCGAAG GAAGGCCATATTCTTTCACC-3 0 ) by using the BLOCK-iT RNAi Designer (Invitrogen). All the lentiviral miRNA or short hairpin RNA expression plasmids were constructed by introducing the annealed oligo duplex into the BLOCK-iT Inducible H1 RNAi Entry Vector (Invitrogen).
Microarray and quantitative real-time PCR
Total cellular RNAs were isolated using the Trizol reagent (Invitrogen) according to manufacturer's instructions. Total RNA concentration was quantified using spectrophotometer with absorbance at 260 nm. For miRNA reverse transcription-PCR, 5 ng of total RNA was subjected to reverse transcription using the Taqman microRNA reverse transcription kit (Applied Biosystems/Life Technologies, Grand Island, NY, USA) according to the manufacturer's instructions. Each cDNA generated was amplified by quantitative PCR using Universal PCR Master Mix (without AmpErase UNG) with sequence-specific primers from the TaqMan microRNA assays on an Applied Biosystems 7900HT sequence detection system (Applied Biosystems). For the EMT-associated gene reverse transcription-PCR, 2 mg of total RNA was subjected to reverse transcription using the Superscript III First-Strand Synthesis SuperMix (Invitrogen) according to the manufacturer's instructions. cDNA was quantified by real-time -PCR using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) with the primers listed in Supplementary Table 1 on the Bio-Rad iQ5 Real-Time PCR detection system (Bio-Rad). The expression levels were quantified using comparative Ct method, 52 and normalized using the expression of U6 small nuclear RNA or glyceraldehyde-3-phosphate dehydrogenase housekeeping gene.
Luciferase reporter assay
To perform luciferase reporter assay, 293T cells grown in a 24-well plate were contransfected with 200 ng of recombinant pCDNA-Luc, 2 ng of pRL-SV40 renilla luciferase control plasmid (Promega, Madison, WI, USA) and 20 nM miRNA mimics or antagomir using FuGENE 6 transfection reagent (Promega). Forty-eight hours after transfection, cells were harvested, and reporter assays were performed using a Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. Luciferase activity was measured on the GloMax 96 Microplate Luminometer (Promega).
Western blotting
Cell pellets were lysed in modified RIPA buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, EDTA) containing 1 mM phenylmethanesulfonylfluoride and 1% complete protease inhibitor cocktail (Roche Applied Science; Indianapolis, IN, USA). After quantification, equal amounts of lysate were separated by SDS-PAGE and then transferred onto poly(-vinylidene fluoride) membranes (Millipore, Billerica, MA, USA). Membranes were blocked in 5% nonfat milk and incubated with anti-ERG (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA, and Biocare Medical; Concord, CA, USA), anti-b tubulin (1:10 000, Sigma, St Louis, MO, USA) and anti-b actin (1:10 000, Sigma) primary antibodies, followed by incubation with goat-anti-rabbit or goat-anti-mouse secondary antibody conjugated with horseradish peroxidase (1:5000, Santa Cruz). The protein signals were visualized by fluography using an enhanced chemiluminescence system (Thermo Scientific, Rockford, IL, USA).
Immunofluorescence staining Cultured cells (1 Â 10 5 ) on glass coverslips were stained by an indirect immunofluorescence method. Cells were fixed in fixation buffer (4% paraformaldehyde in PBS, pH 7.4) and permeabilized in PBS buffer containing 0.5% Triton X-100 and 5% BSA. Cells were then stained with primary anti-E-cadherin (1:100, Cell Signaling, Danvers, MA, USA) or anti-Ncadherin (1:100, Cell Signaling), followed by incubation with Alexa Fluor 555-conjugated anti-rabbit or anti-mouse IgG (1:400, Molecular Probe, Eugene, OR, USA) as secondary antibodies. After staining, samples were mounted with SlowFade Gold antifade reagent with 4 0 -6-diamidino-2-phenylindole (Molecule Probe) for nuclear counterstain. Images were collected by using microscope with Â 200 magnification.
Invasion and wound scratch assay
For the invasion assay, cells (2 Â 10 4 ) were suspended in serum-free medium and added into the Matrigel (Becton Dickinson, Franklin Lakes, NJ, USA)-coated cell culture inserts of Transwell with 8 mm pore 24-well plate (Corning Life Sciences; Tewksbury MA) for 48 h. Invaded cells on the bottom of the insert membrane were stained with crystal violet then subsequently extracted and detected on a standard microplate reader at 540 nm absorbance. For the wound scratch assay, cells (2 Â 10 5 ) were seeded in a 12-well culture dish and grown up to 90% confluence. A single wound was made in the center of cell monolayer and cell debris was removed by washing twice with PBS. Complete medium was added and cells were allowed to migrate into the clearing area for 48 h. The wound closure areas were visualized under an inverted microscope with Â 100 magnification, and the migrated cells were counted.
Proliferation assay
Cells were seeded (2.5 Â 10 4 per well) in triplicates in 48-well plates. Cell growth was monitored by using the cell proliferation kit I (MTT; Roche Applied Science) at 1, 3, 6 and 9 days according to the manufacturer's instructions.
Xenograft assay
All experimental procedures using animals were approved by the Institutional Animal Care and Use Committee of University of CaliforniaDavis. 1 Â 10 6 cells in 100 ml of 50% Matrigel were subcutaneous injected 
